drugset
drugset / Trial / NCT04762160

SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma

NCT04762160 ↗

Phase 2 Terminated 5 enrolled Epizyme, Inc. Swedish Cancer Institute · collab
NaSingle-groupOpen-labelTreatment

Summary

This study evaluates the safety and efficacy of combining the EZH2 inhibitor tazemetostat with rituximab in R/R FL subjects previously treated with at least 2 standard prior systemic treatment regimens where at least 1 anti-CD20-based regimen was used.

Timeline

Start
2020-12-15
Primary completion
2022-03-22
Completion
2022-03-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Rituximab Monoclonal antibody 375 mg/m2 Subcutaneous
Subject Tazemetostat Small molecule 800 mg Oral

Indications

follicular lymphoma